TSHA Taysha Gene Therapies (TSHA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001806310
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
141
13F, latest reported quarter
What the filings say about TSHA
Insiders, 180 days
-$1.2M net sold
1 seller · 0% of sales under a 10b5-1 plan
Taysha Gene Therapies insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Taysha Gene Therapies, Inc. insiders sold a net $1.2M of stock across 63 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 10 earlier Form 4 trades (code P or S) here by this insider (2 buys, 8 sales), the last on Apr 10, 2026.
- +81.9% median (+81.9% mean) 90-day return after 2 previous buys.
- The trade is 21.4% of the 936,410 shares held after it.
- No other insider sold within 30 days.
- 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and Head of R&D Nagendran Sukumar sold about $1.2M of TSHA on Jul 10, 2026, the largest insider sale at the company on our record; 141 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (2 buys, 7 sales), the last on Jan 26, 2026.
- +81.9% median (+81.9% mean) 90-day return after 2 previous buys.
- The trade is 17.6% of the 1,136,410 shares held after it.
- No other insider sold within 30 days.
- 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and Head of R&D Nagendran Sukumar sold about $892.0K of TSHA on Apr 10, 2026; 141 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Jan 26, 2026.
- The trade is 0.1% of the 1,442,131 shares held after it.
- 2 other insiders sold within 30 days.
- 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF FINANCIAL OFFICER Alam Kamran sold about $7.5K of TSHA on Feb 4, 2026; 2 other insiders sold within 30 days and 141 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (2 buys, 6 sales), the last on Jan 23, 2026.
- +81.9% median (+81.9% mean) 90-day return after 2 previous buys.
- The trade is 2.0% of the 1,317,389 shares held after it.
- 2 other insiders sold within 30 days.
- 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and Head of R&D Nagendran Sukumar sold about $124.1K of TSHA on Jan 26, 2026; 2 other insiders sold within 30 days and 141 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Jan 23, 2026.
- The trade is 1.4% of the 2,908,257 shares held after it.
- 2 other insiders sold within 30 days.
- 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Nolan Sean P. sold about $190.4K of TSHA on Jan 26, 2026; 2 other insiders sold within 30 days and 141 funds added in the latest 13F quarter.63 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$1.2M over 180 days
below 65% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
141 funds bought in last quarter
more than 80% of Pharma & Biotech
Revenue
+17.3% year over year
more than 65% of Pharma & Biotech
Margin
-1115.3% net margin
below 87% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
23.6% of the float short (float per yahoo 2026-10-26) · 11.2 days to cover · settled 2026-09-30
more than 89% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch TSHA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-14.0%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns TSHA: institutional holders (13F)
13F holdings, latest reported quarter
23,888,888 sh
$162.7M
23,555,648 sh
$160.4M
22,713,118 sh
$154.7M
20,691,927 sh
$140.9M
19,415,000 sh
$132.2M
Congress trades in TSHA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
TSHA planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Nagendran Sukumar
Filed 2026-07-10
$1.3M
TSHA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
ALPS Medical Breakthroughs ETF
$1.7M position · as of 2026-05-31
1.0%
Polen 5Perspectives Small Growth Fund
$606.1K position · as of 2026-07-31
1.0%
Virtus Biotech Clinical Trials Etf
$319.0K position · as of 2026-07-31
0.7%
Harbor Active Small Cap Growth ETF
$179.5K position · as of 2026-07-31
0.7%
VOYA SMALL COMPANY PORTFOLIO
$778.9K position · as of 2026-06-30
0.4%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$37.9M position · as of 2026-06-30
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 3
2 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Sean Nolan
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$4.1M
$18.3M
$2.1M
+211%
n/a
2024
$4.7M
$4.7M
$3.1M
-2%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $1.2M sold by insiders over 180 days, 141 funds added last quarter. Each figure is a federal filing, dated the day it went public.
TSHA financials
Revenue growth
+17.3%
XBRL, annual
Net margin
-1115.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$5.5M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM TSHA
| FY Dec 2025 | $9.8M |
| FY Dec 2024 | $8.3M |
| FY Dec 2023 | $15.5M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $0 |
| Mar 2026 | $0 |
| Dec 2025 | $5.5M |
| Sep 2025 | $0 |
| Jun 2025 | $2.0M |
| Mar 2025 | $2.3M |
| Dec 2024 | $2.0M |
| Sep 2024 | $1.8M |
At each fiscal year end
Single quarter
Net margin, TTM
-2,728%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM TSHA
| FY Dec 2025 | -1,115% |
| FY Dec 2024 | -1,072% |
| FY Dec 2023 | -722.1% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -507.8% |
| Sep 2025 | n/a |
| Jun 2025 | -1,354% |
| Mar 2025 | -935.2% |
| Dec 2024 | -929.0% |
| Sep 2024 | -1,428% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$132.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM TSHA
| FY Dec 2025 | -$93.8M |
| FY Dec 2024 | -$81.6M |
| FY Dec 2023 | -$76.9M |
| FY Dec 2022 | -$109.0M |
| FY Dec 2021 | -$132.3M |
| Jun 2026 | -$40.4M |
| Mar 2026 | -$40.9M |
| Dec 2025 | -$27.0M |
| Sep 2025 | -$24.3M |
| Jun 2025 | -$20.2M |
| Mar 2025 | -$22.4M |
| Dec 2024 | -$18.3M |
| Sep 2024 | -$21.6M |
At each fiscal year end
Single quarter
Debt to equity
0.13x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity TSHA
| FY Dec 2025 | 0.20x |
| FY Dec 2024 | 0.61x |
| FY Dec 2023 | 0.54x |
| FY Dec 2022 | 40.01x |
| FY Dec 2021 | 0.39x |
| Jun 2026 | 0.13x |
| Mar 2026 | 0.23x |
| Dec 2025 | 0.20x |
| Sep 2025 | 0.23x |
| Jun 2025 | 0.17x |
| Mar 2025 | 0.77x |
| Dec 2024 | 0.61x |
| Sep 2024 | 0.48x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-2.68x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt TSHA
| FY Dec 2025 | -1.86x |
| FY Dec 2024 | -1.85x |
| FY Dec 2023 | -1.80x |
| FY Dec 2022 | -2.33x |
| FY Dec 2021 | -3.15x |
| Jun 2026 | -2.68x |
| Mar 2026 | -2.29x |
| Dec 2025 | -1.86x |
| Sep 2025 | -1.67x |
| Jun 2025 | -2.00x |
| Mar 2025 | -1.97x |
| Dec 2024 | -1.85x |
| Sep 2024 | -1.84x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-47.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity TSHA
| FY Dec 2025 | -68.5% |
| FY Dec 2024 | -121.9% |
| FY Dec 2023 | -294.0% |
| FY Dec 2022 | -344.7% |
| FY Dec 2021 | -100.7% |
| Jun 2026 | -47.1% |
| Mar 2026 | -97.3% |
| Dec 2025 | -68.5% |
| Sep 2025 | -64.9% |
| Jun 2025 | -51.9% |
| Mar 2025 | -159.3% |
| Dec 2024 | -121.9% |
| Sep 2024 | -114.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-37.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets TSHA
| FY Dec 2025 | -43.3% |
| FY Dec 2024 | -53.6% |
| FY Dec 2023 | -74.6% |
| FY Dec 2022 | -97.6% |
| FY Dec 2021 | -73.8% |
| Jun 2026 | -37.2% |
| Mar 2026 | -59.2% |
| Dec 2025 | -43.3% |
| Sep 2025 | -40.2% |
| Jun 2025 | -34.7% |
| Mar 2025 | -59.6% |
| Dec 2024 | -53.6% |
| Sep 2024 | -12.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital TSHA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-40.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed TSHA
| FY Dec 2025 | -49.0% |
| FY Dec 2024 | -67.7% |
| FY Dec 2023 | -72.6% |
| FY Dec 2022 | -144.0% |
| FY Dec 2021 | -83.7% |
| Jun 2026 | -40.7% |
| Mar 2026 | -66.9% |
| Dec 2025 | -49.0% |
| Sep 2025 | -46.5% |
| Jun 2025 | -39.6% |
| Mar 2025 | -76.9% |
| Dec 2024 | -67.7% |
| Sep 2024 | -105.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing TSHA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 3.19x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$978.6M
market value at close 2026-10-27 on 2026-08-11 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value TSHA
| FY Dec 2025 | $1.2B |
| FY Dec 2024 | $259.5M |
| FY Dec 2023 | $227.5M |
| FY Dec 2022 | $91.2M |
| FY Dec 2021 | $336.3M |
| Jun 2026 | $1.6B |
| Mar 2026 | $1.1B |
| Dec 2025 | $1.2B |
| Sep 2025 | $645.5M |
| Jun 2025 | $224.2M |
| Mar 2025 | $210.8M |
| Dec 2024 | $259.5M |
| Sep 2024 | $297.2M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-9.6%
TTM free cash flow over market value at close 2026-10-27
FCF yield TSHA
| FY Dec 2025 | -6.2% |
| FY Dec 2024 | -23.0% |
| FY Dec 2023 | -23.2% |
| FY Dec 2022 | -77.2% |
| FY Dec 2021 | -29.5% |
| Jun 2026 | -6.8% |
| Mar 2026 | -8.7% |
| Dec 2025 | -6.2% |
| Sep 2025 | -9.5% |
| Jun 2025 | -16.6% |
| Mar 2025 | -29.5% |
| Dec 2024 | -23.0% |
| Sep 2024 | -19.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing TSHA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $9.8M | $8.3M | $15.5M | $2.5M |
| Operating income | -$110.5M | -$91.5M | -$72.4M | -$162.4M |
| Net income | -$109.0M | -$89.3M | -$111.6M | -$166.0M |
| EPS (diluted) | -0.34 | -0.36 | -0.96 | -3.78 |
| Operating cash flow | -$93.1M | -$81.2M | -$73.0M | -$88.4M |
| Cash | $319.8M | $139.0M | $143.9M | $87.9M |
| Long-term debt | $50.1M | $43.9M | $40.5M | $38.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
TSHA Stock Sonar score 6/7 axes
Find similar shapesCompareTSHA ranks highest on growth (65th percentile) and profitability (56th), and lowest on insider conviction (17th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
TSHA filings, in plain words
Are Taysha Gene Therapies insiders buying or selling TSHA?
In the 180 days to 2026-10-28, Taysha Gene Therapies insiders were net sellers, a net $1.2M across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-28, Taysha Gene Therapies insiders were net sellers of TSHA, a net $1.2M across purchases and sales reported on Form 4 by 1 seller. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
